CN103003296A - 多肽 - Google Patents

多肽 Download PDF

Info

Publication number
CN103003296A
CN103003296A CN2011800330970A CN201180033097A CN103003296A CN 103003296 A CN103003296 A CN 103003296A CN 2011800330970 A CN2011800330970 A CN 2011800330970A CN 201180033097 A CN201180033097 A CN 201180033097A CN 103003296 A CN103003296 A CN 103003296A
Authority
CN
China
Prior art keywords
albumin bound
bound polypeptide
polypeptide
seq
fusion rotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800330970A
Other languages
English (en)
Chinese (zh)
Inventor
卡罗琳·埃克布拉德
L·亚伯拉罕森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affibody AB
Original Assignee
Affibody AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody AB filed Critical Affibody AB
Priority to CN201910770466.2A priority Critical patent/CN110437321A/zh
Priority to CN201910770209.9A priority patent/CN110437320B/zh
Publication of CN103003296A publication Critical patent/CN103003296A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2011800330970A 2010-07-09 2011-07-08 多肽 Pending CN103003296A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201910770466.2A CN110437321A (zh) 2010-07-09 2011-07-08 多肽
CN201910770209.9A CN110437320B (zh) 2010-07-09 2011-07-08 多肽

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39928510P 2010-07-09 2010-07-09
US61/399,285 2010-07-09
US40356110P 2010-09-17 2010-09-17
US61/403,561 2010-09-17
PCT/EP2011/061623 WO2012004384A2 (en) 2010-07-09 2011-07-08 Polypeptides

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201910770209.9A Division CN110437320B (zh) 2010-07-09 2011-07-08 多肽
CN201910770466.2A Division CN110437321A (zh) 2010-07-09 2011-07-08 多肽

Publications (1)

Publication Number Publication Date
CN103003296A true CN103003296A (zh) 2013-03-27

Family

ID=44630120

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2011800330970A Pending CN103003296A (zh) 2010-07-09 2011-07-08 多肽
CN201910770209.9A Active CN110437320B (zh) 2010-07-09 2011-07-08 多肽
CN201910770466.2A Pending CN110437321A (zh) 2010-07-09 2011-07-08 多肽

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201910770209.9A Active CN110437320B (zh) 2010-07-09 2011-07-08 多肽
CN201910770466.2A Pending CN110437321A (zh) 2010-07-09 2011-07-08 多肽

Country Status (21)

Country Link
US (3) US9211344B2 (https=)
EP (2) EP2933262B1 (https=)
JP (2) JP5827994B2 (https=)
KR (1) KR101884654B1 (https=)
CN (3) CN103003296A (https=)
AU (1) AU2011275766B2 (https=)
BR (1) BR112013000452A2 (https=)
CA (1) CA2804002C (https=)
DK (2) DK2933262T3 (https=)
ES (2) ES2676403T3 (https=)
IL (1) IL223989B (https=)
LT (1) LT2933262T (https=)
MX (1) MX2013000314A (https=)
MY (1) MY161679A (https=)
NO (1) NO2933262T3 (https=)
NZ (1) NZ604805A (https=)
PL (2) PL2590993T3 (https=)
RU (1) RU2577964C2 (https=)
TR (1) TR201809437T4 (https=)
WO (1) WO2012004384A2 (https=)
ZA (1) ZA201300994B (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103957926A (zh) * 2011-07-08 2014-07-30 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
CN105658228A (zh) * 2013-08-28 2016-06-08 瑞典孤儿比奥维特鲁姆有限公司 结合人类补体c5的稳定多肽
CN107454904A (zh) * 2015-04-02 2017-12-08 分子组合公司 对血清白蛋白具有结合特异性的经设计的锚蛋白重复结构域
CN113416683A (zh) * 2021-06-01 2021-09-21 南昌大学 一种大肠杆菌Nissle 1917基因工程菌及其制备方法和应用
US12221473B2 (en) 2017-07-11 2025-02-11 Alexion Pharmaceuticals, Inc. Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
CN103003296A (zh) * 2010-07-09 2013-03-27 阿菲博迪公司 多肽
PT2621515T (pt) 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
BR112013029892A2 (pt) 2011-05-21 2016-12-20 Macrogenics Inc polipeptídeo, molécula de ligação a antígeno, diacorpo e uso de uma porção polipeptídica de uma proteína de ligação a soro desimunizada
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
EP3511339B1 (en) 2012-02-20 2025-04-09 IPC Research, LLC Polypeptides binding to human complement c5
JP2015512902A (ja) * 2012-03-28 2015-04-30 アフィボディ・アーベー 経口投与
JP2020033372A (ja) * 2012-03-28 2020-03-05 アフィボディ・アーベー 経口投与
WO2014048977A1 (en) * 2012-09-25 2014-04-03 Affibody Ab Albumin binding polzpeptide
JP6440618B2 (ja) 2012-10-05 2018-12-19 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド
WO2014064238A1 (en) * 2012-10-25 2014-05-01 Affibody Ab Method for the separation of proteins containing an albumin-binding
CA2889037C (en) 2012-10-25 2021-06-22 Affibody Ab Abd binding polypeptide
WO2014076177A1 (en) * 2012-11-14 2014-05-22 Affibody Ab New polypeptide
WO2014076179A1 (en) 2012-11-14 2014-05-22 Affibody Ab New polypeptide
JP6577868B2 (ja) * 2012-12-19 2019-09-18 アフィボディ・アーベー 新規ポリペプチド
HK1213194A1 (zh) 2013-03-14 2016-06-30 Daiichi Sankyo Co., Ltd. 用於新型的结合蛋白质pcsk9
AU2014230018B2 (en) * 2013-03-15 2018-02-22 Affibody Ab New polypeptides
MX2015014438A (es) 2013-04-18 2016-05-18 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
EP3010527B1 (en) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Method for assessing protein identity and stability
MX367423B (es) 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
CN120242030A (zh) 2013-11-11 2025-07-04 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
US10167322B2 (en) 2013-12-20 2019-01-01 Affibody Ab Engineered albumin binding polypeptide
WO2015177175A2 (en) 2014-05-22 2015-11-26 Pieris Ag Novel specific-binding polypeptides and uses thereof
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
MX386297B (es) 2014-09-29 2025-03-18 Univ Duke Moleculas biespecificas que comprenden un brazo orientado a la envoltura vih-1.
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3245224B1 (en) 2015-01-12 2020-07-15 Affibody AB Il-17a-binding polypeptides
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
KR20180038553A (ko) 2015-08-25 2018-04-16 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
CN111164104A (zh) 2017-08-09 2020-05-15 麻省理工学院 白蛋白结合肽缀合物及其方法
CN108362873B (zh) * 2018-02-13 2021-06-01 苏州仁端生物医药科技有限公司 一种镉离子检测试剂盒及其应用
JP7545894B2 (ja) * 2018-03-13 2024-09-05 アフィボディ アクティエボラーグ 新規足場に基づくポリペプチド
CN113710229B (zh) 2019-02-25 2026-01-06 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
CA3138805A1 (en) 2019-06-04 2020-12-10 Johannes Schilling Designed ankyrin repeat domain with improved stability
EP4017521A1 (en) 2019-09-02 2022-06-29 Biotest AG Factor viii protein with increased half-life
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
WO2021089695A1 (en) 2019-11-05 2021-05-14 Affibody Ab Polypeptides
CN115298193B (zh) 2020-02-05 2026-03-31 伊莱利利公司 串联树脂反应器的肽合成仪
US20230190881A1 (en) 2020-02-17 2023-06-22 Biotest Ag Subcutaneous administration of factor viii
EP3878515A1 (en) 2020-03-09 2021-09-15 Hober Biotech AB Therapeutic agent targeting her2
KR20230123989A (ko) 2020-12-21 2023-08-24 애피바디 에이비 신규 폴리펩티드
EP4291251B1 (en) 2021-02-15 2025-02-19 Affibody AB Her2-binding polypeptide
AR128475A1 (es) 2022-02-08 2024-05-15 Affibody Ab Polipéptidos y proteínas de fusión con afinidad de unión por tslp
TW202448926A (zh) 2023-02-17 2024-12-16 比利時商艾伯霖克斯公司 結合新生兒fc受體之多肽
CN121038816A (zh) 2023-05-04 2025-11-28 阿菲博迪公司 新多肽
WO2024263059A1 (ru) * 2023-06-21 2024-12-26 Общество С Ограниченной Ответственностью "Герофарм" Гибридные белки-предшественники пептидных иммуногенов ‒ компонентов вакцины против covid-19
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1
TW202545983A (zh) 2024-01-25 2025-12-01 瑞典商艾菲博迪公司 新穎多肽

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101294187A (zh) * 2008-06-06 2008-10-29 暨南大学 一种缓释生物活性多肽的方法与应用
CN101528767A (zh) * 2006-10-11 2009-09-09 埃博灵克斯股份有限公司 以基本不依赖pH的方式结合血清蛋白的氨基酸序列、包括其的化合物、及其用途
CN101765608A (zh) * 2007-07-31 2010-06-30 阿菲博迪公司 新组合物、方法及应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6362225B1 (en) 1999-01-21 2002-03-26 George Andreakos Target therapies for treating common viral infections
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US7288265B1 (en) 2000-10-16 2007-10-30 Lectec Corporation Treating viral infection at smallpox vaccination site
AU2002246737B2 (en) * 2000-12-29 2007-03-01 Savient Pharmaceuticals, Inc. Specific human antibodies for selective cancer therapy
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1631308B1 (en) 2003-05-30 2013-07-31 Amylin Pharmaceuticals, LLC Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
JP5634008B2 (ja) * 2004-04-06 2014-12-03 アフィボディ・アーベー 新規の使用および方法
US20050282756A1 (en) 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
CN101128487B (zh) * 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
EA200802348A1 (ru) * 2006-05-24 2009-08-28 Байер Шеринг Фарма Акциенгезельшафт ЧЕЛОВЕЧЕСКИЙ ВЫСОКОАФФИННЫЙ И ГУМАНИЗИРОВАННЫЙ АНТИ-α5β1 ИНТЕГРИН С ФУНКЦИЕЙ БЛОКИРУЮЩЕГО АНТИТЕЛА С ОСЛАБЛЕННОЙ ИММУНОГЕННОСТЬЮ
AU2007284801A1 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
AU2007293614A1 (en) * 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
EP2077272A1 (en) 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
NZ588603A (en) 2008-03-26 2012-03-30 Oramed Ltd Methods and compositions for oral administration of a protein of up to 100000 Daltaons, a first protease inhibitor and a second protease inhibitor wherein said protease inhibitors inhibit trypsin
CN101294178A (zh) 2008-05-26 2008-10-29 江南大学 一种用两阶段培养法提高发酵生产透明质酸产量的方法
JP5740689B2 (ja) 2008-08-18 2015-06-24 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
EP2437767B1 (en) 2009-06-01 2015-07-08 MedImmune, LLC Molecules with extended half-lives and uses thereof
CN103003296A (zh) 2010-07-09 2013-03-27 阿菲博迪公司 多肽
US20120027058A1 (en) 2010-07-29 2012-02-02 The Regents Of The University Of Michigan Portable, wireless multi-channel impedance analyzer
PT2621515T (pt) 2010-09-28 2017-07-12 Aegerion Pharmaceuticals Inc Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada
CN103347532A (zh) 2011-02-04 2013-10-09 爱奇司治疗公司 口服可生物利用肽药物组合物及其方法
CN103957926B (zh) 2011-07-08 2018-07-03 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
JP2015512902A (ja) 2012-03-28 2015-04-30 アフィボディ・アーベー 経口投与
WO2014048977A1 (en) 2012-09-25 2014-04-03 Affibody Ab Albumin binding polzpeptide
US10167322B2 (en) 2013-12-20 2019-01-01 Affibody Ab Engineered albumin binding polypeptide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528767A (zh) * 2006-10-11 2009-09-09 埃博灵克斯股份有限公司 以基本不依赖pH的方式结合血清蛋白的氨基酸序列、包括其的化合物、及其用途
CN101765608A (zh) * 2007-07-31 2010-06-30 阿菲博迪公司 新组合物、方法及应用
CN101294187A (zh) * 2008-06-06 2008-10-29 暨南大学 一种缓释生物活性多肽的方法与应用

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103957926A (zh) * 2011-07-08 2014-07-30 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
CN103957926B (zh) * 2011-07-08 2018-07-03 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
CN105658228A (zh) * 2013-08-28 2016-06-08 瑞典孤儿比奥维特鲁姆有限公司 结合人类补体c5的稳定多肽
CN105658228B (zh) * 2013-08-28 2020-02-07 瑞典孤儿比奥维特鲁姆有限公司 结合人类补体c5的稳定多肽
CN107454904A (zh) * 2015-04-02 2017-12-08 分子组合公司 对血清白蛋白具有结合特异性的经设计的锚蛋白重复结构域
US12221473B2 (en) 2017-07-11 2025-02-11 Alexion Pharmaceuticals, Inc. Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof
CN113416683A (zh) * 2021-06-01 2021-09-21 南昌大学 一种大肠杆菌Nissle 1917基因工程菌及其制备方法和应用

Also Published As

Publication number Publication date
AU2011275766A1 (en) 2013-01-10
AU2011275766B2 (en) 2015-10-22
JP2013534421A (ja) 2013-09-05
HK1182719A1 (en) 2013-12-06
DK2933262T3 (en) 2018-06-25
MX2013000314A (es) 2013-01-29
BR112013000452A2 (pt) 2020-02-11
JP2016053047A (ja) 2016-04-14
EP2590993B1 (en) 2015-05-06
US20160108095A1 (en) 2016-04-21
US10329331B2 (en) 2019-06-25
NO2933262T3 (https=) 2018-09-29
PL2590993T3 (pl) 2015-10-30
KR20130034043A (ko) 2013-04-04
IL223989B (en) 2018-10-31
HK1209761A1 (en) 2016-04-08
RU2577964C2 (ru) 2016-03-20
CA2804002C (en) 2021-07-20
KR101884654B1 (ko) 2018-08-02
TR201809437T4 (tr) 2018-07-23
CN110437320A (zh) 2019-11-12
WO2012004384A2 (en) 2012-01-12
PL2933262T3 (pl) 2018-10-31
ES2540114T3 (es) 2015-07-08
RU2013102953A (ru) 2014-08-20
ES2676403T3 (es) 2018-07-19
LT2933262T (lt) 2018-07-10
DK2590993T3 (en) 2015-06-29
CN110437321A (zh) 2019-11-12
US9211344B2 (en) 2015-12-15
EP2933262A1 (en) 2015-10-21
CA2804002A1 (en) 2012-01-12
MY161679A (en) 2017-05-15
CN110437320B (zh) 2023-10-20
NZ604805A (en) 2014-09-26
EP2933262B1 (en) 2018-05-02
US20140162956A1 (en) 2014-06-12
JP6486810B2 (ja) 2019-03-20
ZA201300994B (en) 2020-05-27
WO2012004384A3 (en) 2012-03-29
JP5827994B2 (ja) 2015-12-02
US20190375799A1 (en) 2019-12-12
EP2590993A2 (en) 2013-05-15

Similar Documents

Publication Publication Date Title
CN103003296A (zh) 多肽
CN109071606A (zh) 利用IgG结合肽的位点特异性放射性同位素标记抗体
AU2014314222B2 (en) Stable polypeptides binding to human complement C5
KR102140557B1 (ko) 단백질-단백질 결합체를 형성 매개 펩타이드 및 이를 이용한 단백질-단백질 결합체 형성 방법
Frejd Novel alternative scaffolds and their potential use for tumor targeted radionuclide therapy
HK1182719B (en) Polypeptides
HK1209761B (en) Polypeptides
Aoki Chemical Synthesis of Mirror-Image VHHs and Evaluation of Their Immunogenicity
HK40050539B (en) Stable polypeptides binding to human complement c5
HK40050539A (en) Stable polypeptides binding to human complement c5

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130327